Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance



Status:Terminated
Conditions:Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/11/2018
Start Date:January 25, 2005
End Date:March 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma

Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab
consolidation and maintenance therapy every 3 months until disease progression

The objective of this study is to estimate the median progression-free survival for patients
receiving this regimen, along with the rate of complete response at 6 months, toxicities
associated with this regimen, and laboratory correlates. Subjects will receive the
Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and
maintenance therapy every 3 months until disease progression.

Inclusion Criteria:

- Patients with biopsy-proven non-hodgkins lymphoma of follicular grade 1, 2, or 3

- Meeting FLIPI criteria for intermediate or high risk.

- No prior chemotherapy, radiotherapy or immunotherapy for lymphoma;

- Patients may not have known HIV infection, and must not be Hepatitis B Surface Antigen
positive.

Exclusion Criteria:

- May not be pregnant or breastfeeding, have documented CNS (Central Nervous System)
disease, G-CSF (Granulocyte Colony Stimulating Facto) or GM-CSF
(Granulocyte/Macrophage Colony Stimulating Factor) within 2 weeks prior
We found this trial at
1
site
University of Wisconsin
Madison, Wisconsin 53792
(608) 263-2400
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials